ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Sirion Therapeutics Announces Positive Phase III Results For Difluprednate
Sirion Therapeutics,
Inc., a privately held ophthalmic-focused biopharmaceutical company,
announced positive preliminary results from its Phase III difluprednate
(ST-601) program, which evaluated the steroid's potential to rapidly
resolve inflammation in the eye following ocular surgery.
"We are very pleased with the data that demonstrate difluprednate's
potential as a potent, well-tolerated steroid treatment for post-operative
inflammation," said Dr. Roger Vogel, Sirion's Chief Medical Officer. "Based
on these data, Sirion is moving forward with its plans to submit a New Drug
Application to the FDA."
The Phase III program consisted of two multi-center, randomized,
double- masked studies that compared the safety and efficacy of
difluprednate 0.05% to placebo, dosed two (BID) or four (QID) times daily
beginning 24 hours after surgery. The studies included 439 subjects who
presented with Grade 2 (an inflammatory cell count greater than or equal to
10) or higher the day after surgery. Inflammation was measured by the
number of cells in the anterior chamber of the eye with a Grade 0 equaling
less than or equal to one cell. The primary efficacy endpoint measured the
proportion of subjects whose inflammation reached Grade 0 at Day 8.
Both difluprednate dosing regimens were superior to placebo at the
primary endpoint, reaching high statistical significance at Day 8 and
maintaining superiority through both the treatment period (Day 15) and the
tapering period (Day 29). At Day 15, 56% of subjects on the BID regimen
reached Grade 0 compared to 16% in the control group (p
Sirion terapeutice Announces pozitive de fazã III Rezultate pentru Difluprednate - Sirion Therapeutics Announces Positive Phase III Results For Difluprednate - articole medicale engleza - startsanatate